Latest news with #Pilot
!['The Pedal [Could] Shift Out of Position:' Honda Recalls a Quarter-Million Cars Over Faulty Brake Pedals](/_next/image?url=https%3A%2F%2Fcdn.motor1.com%2Fimages%2Fmgl%2F40Zv31%2Fs1%2F2023-honda-pilot-trailsport-exterior-front-quarter.jpg&w=3840&q=100)
!['The Pedal [Could] Shift Out of Position:' Honda Recalls a Quarter-Million Cars Over Faulty Brake Pedals](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fmotor1.com.png&w=48&q=75){kind=small}
Motor 1
2 days ago
- Automotive
- Motor 1
'The Pedal [Could] Shift Out of Position:' Honda Recalls a Quarter-Million Cars Over Faulty Brake Pedals
Honda has issued a recall for 259,033 vehicles in the United States. The cars may have a brake pedal assembly with an improperly staked pivot pin, which could allow the pedal to shift laterally out of position. If this happens, it could compromise the driver's braking ability and cause a crash. The recall affects the 2023-2025 Honda Pilot , 2023-2025 Acura MDX , and the 2021-2025 Acura TLX . The Pilot makes up most of the recalled cars—184,243 vehicles. Honda estimates that one percent of the affected models have the defect. Honda received its first report of a vehicle experiencing brake pedal movement in April 2024. It received a second report in December 2024 and began investigating the parts inventory from the supplier in February 2025 before determining, earlier this month, to issue a voluntary recall. Honda discovered that when the supplier relocated production from the United States to Mexico, it increased staffing and production to offset any supply shortages. However, the staff failed to perform the staking process due to insufficient training, resulting in brake pedals with unstaked pins. In the Safety Recall Report , Honda states it's not aware of any reported injuries or deaths related to this issue. However, it is aware of three related warranty claims. The company will begin notifying affected customers by the end of July, instructing owners to take their vehicles to a dealer for an inspection. Service technicians will replace the assembly if necessary. Here Are More Recalls To Check Out: Ford Recalls Another One Million Vehicles Volvo Recalls Nearly 500,000 Cars Over a Simple Software Glitch Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Source: National Highway Traffic Safety Administration Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
New York Post
2 days ago
- Automotive
- New York Post
Honda recalls 259K cars over faulty brake pedal that can increase crash, injury risk
Honda Motor is recalling more than 259,000 vehicles in the US over a faulty brake pedal, the National Highway Traffic Safety Administration said this week. A poorly secured pin can make the brake pedal shift out of position, preventing drivers from using the brake and increasing the risk of crash or injury. The recall includes Honda Acura MDX 2023-2025, Acura TLX 2021-2025 and Pilot 2023-2025 vehicles. Honda is recalling more than 259,000 vehicles in the US. Mike Mareen – There have been three warranty claims related to the recall and no reported injuries or deaths linked to the matter, according to the carmaker. About 1% of the 259,033 vehicles included in the recall likely have the defect, Honda estimated in a safety report. Owners should bring their vehicles to a Honda dealership, where they can be inspected and the brake pedal assembly can be fixed free of charge, if necessary. All owners of impacted vehicles will be notified by mail. Letters are expected to be mailed out on July 28, Honda said. The brake pin issue occurred during production at a US plant, which has since closed and moved to Mexico. The new facility has started using a camera sensor to verify whether the pin is securely staked, Honda said. Honda said owners should bring their vehicles to a dealership so they can be inspected and repaired, if necessary. vector_master – Honda launched an investigation in April 2024 after receiving a report of a vehicle experiencing brake pedal movement. It determined the defect existed across certain vehicles on June 5 and decided to issue a recall.
Yahoo
2 days ago
- Business
- Yahoo
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: CONTACT: Media Contact contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: CONTACT: Media Contact contact@
New Indian Express
3 days ago
- Politics
- New Indian Express
Congress questions govt's intention on caste census; BJP says Cong carrying out 'false' propaganda out of frustration
NEW DELHI: The Congress on Tuesday accused the Centre of delaying the caste census, saying its intention appears to be to "buy time, grab headlines and manage the narrative", and asked the government to be transparent about the exercise. Congress general secretary Sachin Pilot said the objective cannot just be to collect data on an individual's caste but to understand the living conditions of these families and create policies to substantially improve their livelihoods. He said there are doubts about the government's intentions on the caste census and pointed out that the required funding for the census is Rs 10,000 crore whereas the government has allocated only Rs 574 crore. His remarks come a day after a Home Ministry spokesperson made it clear that the census will include caste enumeration, following the Congress' charge that the government notification is "silent" on the inclusion of caste in the exercise. "The demand for a caste census was led by the Congress party, particularly by the Leader of Opposition in Lok Sabha, Rahul Gandhi, who has been raising this issue for several years. "Due to the party's continuous and forceful demand, the Modi government has yielded and announced a caste census. However, the facts and figures tell a different story," Pilot said at a press conference at the Congress' Indira Bhawan headquarters here on Tuesday. The government plans to start the exercise in 2027, but the required funding for the census is Rs 10,000 crore, whereas the government has allocated only Rs 574 crore, he pointed out. "The objective is not just to collect data on an individual's caste but to understand the living conditions of these families and create policies to substantially improve their livelihoods. Without tangible data, no state or central government can implement targeted interventions, which is what we aimed to achieve," he said. Initially, the BJP labelled us as "urban naxals" and refused to accept these demands and now, sensing the country's mood, they have accepted the proposal in principle, he said. "However, there seems to be considerable confusion and dissatisfaction regarding it. Therefore, I urge the government to be clear and transparent, avoiding extended deadlines and inadequate budget allocations," Pilot said. "The idea is to accurately assess the status of people living in India, and caste census is the perfect way to do it. Unfortunately, it appears the government's intention is to buy time, grab headlines, and manage the narrative," he said.
